SM 12502Alternative Names: SM-12502
Latest Information Update: 30 Aug 2007
At a glance
- Originator Sumitomo Pharmaceuticals
- Class Antiplatelets
- Mechanism of Action Platelet activating factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Disseminated intravascular coagulation; Shock